TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2905240

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg twice daily
Number of subjects: 295

Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 295
Study: 31978354

Group type: EXPERIMENTAL
Intervention: VXA‐A1.1 (1011 infectious units, orally)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: IIV (full human dose, intramuscular)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: VXA‐A1.1
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: IIV
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 30232107

Group type: EXPERIMENTAL
Intervention: Patients who understood their treatment intent
Number of subjects: 282

Group type: COMPARATOR
Intervention: Patients who did not understand their treatment intent
Number of subjects: 282
Study: 27871601

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline (0.1 mL/kg)
Number of subjects: 68
Study: 24255934

Group type: EXPERIMENTAL
Intervention: Periodontal dressing (Coepak(®) ) for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: No periodontal dressing (Control)
Number of subjects: 24
Study: 22488402

Group type: EXPERIMENTAL
Intervention: Diagnosis of MetSx
Number of subjects: 74

Group type: COMPARATOR
Intervention: Diagnosis of individual cardiovascular risk factors
Number of subjects: 74
Study: 20931097

Group type: EXPERIMENTAL
Intervention: Men (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Women (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low-risk men (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low-risk women (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low-risk younger patients (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low-risk older patients (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Patients who agreed to CC (perceived benefit from CC)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Patients who were disagreeable or made no comment (perceived benefit from CC)
Number of subjects: 237
Study: 18230968

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200 g/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yoghurt (200 g/day for 2 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Number of subjects: 33
Study: 15896564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 28
Study: 12244361

Group type: EXPERIMENTAL
Intervention: Group A (radio forum)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Group B (non-organized listening)
Number of subjects: 70
Study: 11382854

Group type: EXPERIMENTAL
Intervention: Medium Pharyngeal Constrictor Muscles (MPCM) evaluation in OSA patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Medium Pharyngeal Constrictor Muscles (MPCM) evaluation in non-OSA patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Needle biopsy of Vastus Lateralis Muscle (VLM) in OSA patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Needle biopsy of Vastus Lateralis Muscle (VLM) in non-OSA patients
Number of subjects: 22
Study: 7634550

Group type: EXPERIMENTAL
Intervention: Conventional plasma exchange
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cascade filtration
Number of subjects: 22
Study: 2515825

Group type: EXPERIMENTAL
Intervention: acebutolol (10 mg/kg)
Number of subjects: 41
Study: 758131

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU; 300 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 31860742

Group type: EXPERIMENTAL
Intervention: Oral hygiene or scaling and root planning ± placebo or polyunsaturated fatty acids fish oil
Number of subjects: 81
Study: 31542771

Group type: EXPERIMENTAL
Intervention: Withholding milk feeds (for 4 hours before, during and for 4 hours after red cell transfusions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuing milk feeds (before, during and after red cell transfusions)
Number of subjects: 0
Study: 28321995

Group type: EXPERIMENTAL
Intervention: 4% Garcinia mangostana L. pericarp gel (MGA) as local drug delivery with scaling and root planing (SRP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel with scaling and root planing (SRP)
Number of subjects: 50
Study: 25795452

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg QD)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg QD)
Number of subjects: 34
Study: 23442248

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Live vaccine as the most recent vaccination
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Inactivated vaccine as the most recent vaccination
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Children with infection excluded
Number of subjects: 1102
Study: 22024188

Group type: EXPERIMENTAL
Intervention: InFoQI program (intervention arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic NICE registry feedback (control arm)
Number of subjects: 0
Study: 19302699

Group type: EXPERIMENTAL
Intervention: NNTs derived from time-to-event outcomes
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: NNTs derived from binary outcomes
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: NNTs reporting articles
Number of subjects: 734
Study: 16427389

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, or 160 microg/kg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 15605806

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No postoperative radiotherapy (non-irradiated)
Number of subjects: 51
Study: 11574493

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9762741

Group type: EXPERIMENTAL
Intervention: 2% lidocaine medial branch injections
Number of subjects: 18

Group type: COMPARATOR
Intervention: saline medial branch injections
Number of subjects: 18
Study: 7909099

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at 0.4 g/kg body weight
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (0.4% albumin)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 2439559

Group type: EXPERIMENTAL
Intervention: Ventricular ectopic activity (greater than or equal to 10 ventricular premature beats/h or pairs, ventricular tachycardia or multiform complexes)
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: Presence of ventricular ectopic activity
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: Seven categoric definitions of ventricular ectopic activity
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: Clinical criteria (ST depression, cardiomegaly, prior infarction)
Number of subjects: 3290

Group type: COMPARATOR
Intervention: Control group (1,640 patients randomized to placebo therapy)
Number of subjects: 3290
Study: 31436843

Group type: EXPERIMENTAL
Intervention: Sexual health promotion intervention (classroom session, information materials, free condom distribution)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study: 29718329

Group type: EXPERIMENTAL
Intervention: Ridinilazole (200 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study: 27697550

Group type: EXPERIMENTAL
Intervention: Cold condition (local torso cooled)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thermal neutral condition
Number of subjects: 44
Study: 24391142

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/Amlodipine 5 mg (T80/A5)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Amlodipine 5 mg (A5)
Number of subjects: 324
Study: 23548219

Group type: EXPERIMENTAL
Intervention: Intraumbilical vein oxytocin injection (10 IU, 1 mL)
Number of subjects: 178
Study: 21139155

Group type: EXPERIMENTAL
Intervention: Injection with laboratory-prepared, amplified collagen-producing cells derived from dermal fibroblasts and suspended in autologous plasma
Number of subjects: 46

Group type: COMPARATOR
Intervention: Autologous plasma alone
Number of subjects: 46
Study: 18511473

Group type: EXPERIMENTAL
Intervention: HRT, vitamin D(3) and calcium
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vitamin D(3) and calcium alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 88
Study: 16595018

Group type: EXPERIMENTAL
Intervention: Depression information website
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural skills training website (CBT)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 414
Study: 12699514

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs) with fresh gas flows of 1.0, 3.0, or 6.0 l min‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group without HMEs with fresh gas flows of 1.0, 3.0, or 6.0 l min‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group without HMEs
Number of subjects: 90
Study: 10967613

Group type: EXPERIMENTAL
Intervention: Oral iodised oil (1 ml Lipiodol Ultrafluide, 490 mg I)
Number of subjects: 197
Study: 8813041

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Amlodipine (nonischemic cardiomyopathy)
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Placebo (nonischemic cardiomyopathy)
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Amlodipine (ischemic heart disease)
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Placebo (ischemic heart disease)
Number of subjects: 1153
Study: 1430283

Group type: EXPERIMENTAL
Intervention: Irradiated glutaraldehyde‐crosslinked human collagen membrane (test)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Flap reflection alone (control)
Number of subjects: 19
Study: 2430825

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 32
Study: 29813111

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) within 4.5 hours after NA-CRAO
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conservative standard treatment (CST) from the EAGLE trial
Number of subjects: 20
Study: 27974857

Group type: EXPERIMENTAL
Intervention: Incredible Years Parents and Babies (IYPB) program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 25020008

Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention (Stanley and Brown, 2012)
Number of subjects: 0
Study: 22690890

Group type: EXPERIMENTAL
Intervention: CSD communication skills training intervention (2 hour teaching session, deliberate practice, online modules, self-reflection, booster training session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (clinical rotations alone)
Number of subjects: 0
Study: 21246840

Group type: EXPERIMENTAL
Intervention: Acupuncture group 1 (electroacupuncture at Jiaji (EX‐B 2) points of T5‐T7 and Shenshu (BL 23))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture group 2 (electroacupuncture at Neiguan (PC 6), Shenmen (HT 7) and Zusanli (ST 36))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simulation group (analog electrical stimulation at Zusanli (ST 36) and Sanyinjiao (SP 6))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Blank group (no therapy applied)
Number of subjects: 120
Study: 18272507

Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Accelerometer sensor (AS)
Number of subjects: 131
Study: 18428192

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 37) participated in 150 min/wk of supervised gym‐based and home‐based aerobic exercise for 6 months.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual-care group (n = 38) instructed to maintain current physical activity level.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual-care group (n = 38)
Number of subjects: 75
Study: 15196285

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP) 200 microg once daily
Number of subjects: 471

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Oral loratadine (LOR) 10 mg once daily
Number of subjects: 471
Study: 11723015

Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering strategy
Number of subjects: 402

Group type: COMPARATOR
Intervention: Moderate lipid-lowering strategy
Number of subjects: 402
Study: 9161362

Group type: EXPERIMENTAL
Intervention: Softest interface (EVA foam)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stiffest interface (EVA foam)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rigid surface
Number of subjects: 12
Study: 7962376

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3498877

Group type: EXPERIMENTAL
Intervention: Doxycycline (one dose a day)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (two doses a day)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Amoxycillin (three doses a day)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (two doses a day) with written instruction sheet and advice
Number of subjects: 232
Study: 30982100

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (25 billion CFU Lactobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium animalis subs p. Lactis) for 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 24
Study: 28934800

Group type: EXPERIMENTAL
Intervention: Intraarticular pulsed radiofrequency (PRF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intraarticular corticosteroid injection (ICI)
Number of subjects: 40
Study: 25582182

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU) at birth
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants
Number of subjects: 29
Study: 23559419

Group type: EXPERIMENTAL
Intervention: Visual sub‐segmental analysis (VSSA)
Number of subjects: 161
Study: 21900640

Group type: EXPERIMENTAL
Intervention: Low-magnitude whole body vibration with resistive exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (head-down bed rest without intervention)
Number of subjects: 14
Study: 19491910

Group type: EXPERIMENTAL
Intervention: Rituximab, a B‐cell‐depleting anti‐CD20 monoclonal antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study: 16733162

Group type: EXPERIMENTAL
Intervention: 10F, 15F, and 19F Blake drains (group A)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional chest drains (group B)
Number of subjects: 189
Study: 15593174

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Both groups (Doxycycline and Placebo)
Number of subjects: 431
Study: 11380528

Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (1 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1-year oral melatonin treatment
Number of subjects: 24
Study: 8985189

Group type: EXPERIMENTAL
Intervention: Vaccination of health care workers (HCWs)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Vaccination of patients
Number of subjects: 1059
Study: 8250309

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA) with 2.5-5 mg of plain bupivacaine 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SS) with 20 mg of plain bupivacaine 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SS)
Number of subjects: 50
Study: 3300967

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Iproplatin (CHIP)
Number of subjects: 64
Study: 29608107

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 161
Study: 27364049

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units IV, 5 injections spaced 12 hours apart for a total of 200,000 units)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Standard care without Epo
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 476
Study: 24934544

Group type: EXPERIMENTAL
Intervention: 1.7 g DHA (22:6) and 0.6 g EPA (20:5) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study: 22425127

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg) and/or Tamsulosin (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21039311

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18827299

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 16521850

Group type: EXPERIMENTAL
Intervention: 3 g L-Carnitine L-tartrate (LCLT) daily for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3 g placebo (P) daily for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 g L-Carnitine L-tartrate (LCLT)
Number of subjects: 15
Study: 12456937

Group type: EXPERIMENTAL
Intervention: Swaddled (cotton spandex swaddle)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unsaddled
Number of subjects: 26
Study: 9733448

Group type: EXPERIMENTAL
Intervention: Fludarabine 20 mg/m2 body surface area per day for 3 consecutive days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m2 body surface area per day for 3 consecutive days
Number of subjects: 26
Study: 8018458

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg four times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg four times daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2685953

Group type: EXPERIMENTAL
Intervention: Selenium-rich yeast (100 micrograms/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 4318020

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (800 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dichloral phenazone (1,300 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Mandrax (methaqualone 250 mg and diphenhydramine 25 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31928313

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-invasive ventilation
Number of subjects: 0
Study: 30032842

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 26455343

Group type: EXPERIMENTAL
Intervention: PVI + lines (left atrial roof line, mitral isthmus line, and tricuspid isthmus line)
Number of subjects: 122

Group type: COMPARATOR
Intervention: PVI-only
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: PVI + lines
Number of subjects: 122

Group type: COMPARATOR
Intervention: PVI + lines and PVI-only
Number of subjects: 122
Study: 24770930

Group type: EXPERIMENTAL
Intervention: Novel vascular polyester prosthesis coated with a resorbable polymer
Number of subjects: 24
Study: 22486193

Group type: EXPERIMENTAL
Intervention: 0.2% alcohol-free chlorhexidine mouthwash applied twice a day for 30 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.2% alcohol-free chlorhexidine mouthwash
Number of subjects: 70
Study: 19760232

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) with a minimum threshold post-ablation margin of 0.4 cm in HCC group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) with a minimum threshold post-ablation margin of 0.4 cm in colorectal liver metastases group
Number of subjects: 83
Study: 18481115

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing by telephone (3 calls at intervals of 2 months)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing by telephone
Number of subjects: 147